Topic: anti-obesity device
The financing gives ReShape, formerly known as EnteroMedics, money to commercialize its weight loss devices, but the move caused investors to buck.
The round equips Gelesis to get its manufacturing and commercial arms ready for launch should regulators look favorably on its mixed late-phase data.
Allurion Technologies’ goal is to help people realize their full potential with innovative, scalable products.
SGS pulled the CE Certificate of Conformity over the weekend in response to nonconformity to medical device quality management system standards.
Here is Wednesday's dose of medtech news of note.
More than half of subjects who took the hydrogel particles lost weight, encouraging Gelesis to file for approval despite missing another endpoint.
Apollo Endosurgery picked up a CE mark for its weight-loss balloon, which is designed to remain in the stomach for 12 months.
The FDA updated its warning on liquid-filled intragastric balloons used to treat obesity after receiving five new reports of patient deaths.
Harvard University researchers have identified an enzyme that protects cells from harmful fats, which could inform new obesity treatments.
EnteroMedics will modify its obesity-treating neuromodulation system for Galvani Bioelectronics to use in preclinical research.